Epoprostenol sodium for treatment of pulmonary arterial hypertension

Yukihiro Saito, Kazufumi Nakamura, Satoshi Akagi, Toshihiro Sarashina, Kentaro Ejiri, Aya Miura, Aiko Ogawa, Hiromi Matsubara, Hiroshi Itoh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalVascular Health and Risk Management
Volume11
DOIs
Publication statusPublished - May 14 2015

Fingerprint

Epoprostenol
Pulmonary Hypertension
Therapeutics
Hemodynamics
Catheter-Related Infections
Fas Ligand Protein
Cell- and Tissue-Based Therapy
Intravenous Administration
Up-Regulation
Randomized Controlled Trials
Exercise

Keywords

  • Apoptosis
  • Prostacyclin
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Epoprostenol sodium for treatment of pulmonary arterial hypertension. / Saito, Yukihiro; Nakamura, Kazufumi; Akagi, Satoshi; Sarashina, Toshihiro; Ejiri, Kentaro; Miura, Aya; Ogawa, Aiko; Matsubara, Hiromi; Itoh, Hiroshi.

In: Vascular Health and Risk Management, Vol. 11, 14.05.2015, p. 265-270.

Research output: Contribution to journalArticle

@article{8b95007e5e6d48fa9e7563f86a8f87a6,
title = "Epoprostenol sodium for treatment of pulmonary arterial hypertension",
abstract = "The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.",
keywords = "Apoptosis, Prostacyclin, Pulmonary arterial hypertension",
author = "Yukihiro Saito and Kazufumi Nakamura and Satoshi Akagi and Toshihiro Sarashina and Kentaro Ejiri and Aya Miura and Aiko Ogawa and Hiromi Matsubara and Hiroshi Itoh",
year = "2015",
month = "5",
day = "14",
doi = "10.2147/VHRM.S50368",
language = "English",
volume = "11",
pages = "265--270",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Epoprostenol sodium for treatment of pulmonary arterial hypertension

AU - Saito, Yukihiro

AU - Nakamura, Kazufumi

AU - Akagi, Satoshi

AU - Sarashina, Toshihiro

AU - Ejiri, Kentaro

AU - Miura, Aya

AU - Ogawa, Aiko

AU - Matsubara, Hiromi

AU - Itoh, Hiroshi

PY - 2015/5/14

Y1 - 2015/5/14

N2 - The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.

AB - The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.

KW - Apoptosis

KW - Prostacyclin

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84936747789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936747789&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S50368

DO - 10.2147/VHRM.S50368

M3 - Article

VL - 11

SP - 265

EP - 270

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -